Taysha Gene Therapies(TSHA) - 2023 Q4 - Annual Results

Exhibit 99.1 Initial data from cohort one (low dose, 5.7x1014 total vg) in REVEAL pediatric trial expected mid-2024; initial data from cohort two (high dose, 1x1015 total vg) in both trials (adolescent/adult and pediatric) expected in 2H 2024 Conference call and live webcast today at 4:30 PM Eastern Time Dallas – March 19, 2024 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the ...